Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2008

Lee Tong-Young, Tjin Tham Sjin Robert M, Movahedi Shahla, Ahmed Bissan, Pravda Elke A, Lo Kin-Ming, Gillies Stephen D, Folkman Judah, Javaherian Kashi

Abstract excerpt

PURPOSE: The half-life of the antiangiogenic molecule endostatin that has been used in clinical trial is short ( approximately 2 h). In addition, approximately 50% of the clinical grade endostatin molecules lack four amino acids at their NH(2) termini. Lack of these amino acids gives rise to a mo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Half-Life
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Immunoglobulin G

Share to In Situ Nick-End Labeling

Share to Melanoma, Experimental

Share to Mice, SCID

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 18316573
DOI: 10.1158/1078-0432.CCR-07-1530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18316573-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.PMID 18316573Read ↗

Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.Semantic proximity Read ↗

Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivoSemantic proximity Read ↗

Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid TumorsSemantic proximity Read ↗

Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.Semantic proximity Read ↗

The clinical potential of antiangiogenic fragments of extracellular matrix proteinsSemantic proximity Read ↗

Isolation and characterization of the circulating form of human endostatinSemantic proximity Read ↗

N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.Semantic proximity Read ↗

Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis.Semantic proximity Read ↗

Fusion of a Short Peptide that Binds Immunoglobulin G to a Recombinant Protein Substantially Increases Its Plasma Half-Life in MiceSemantic proximity Read ↗

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome.Semantic proximity Read ↗

Half-life extension using serum albumin-binding DARPin® domainsSemantic proximity Read ↗

Disruption of the KEX1 gene inPichia pastoris allows expression of full-length murine and human endostatinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.